Abstract: A method of predicting the risk of recurrence in a subject undergoing treatment for, or having undergone treatment for, clear cell renal cell carcinoma (ccRCC), by comparing the level of extracellular vesicles, preferably microvesicles, expressing carbonic anhydrase 9 (CA9+ MVs) in a sample from the subject with a reference level. Also, a method of diagnosing ccRCC or identifying a risk of developing ccRCC, by comparing the level of CA9+ MVs in a sample from the subject with a reference level.

Abstract: Disclosed is a non-invasive method for assessing in a subject the presence and severity of a liver lesion, or the risk of death or liver-related events, including: 1) performing at least three binary logistic regressions on at least one variable, performed on the same variable(s) but each directed to a different single diagnostic target, thereby obtaining at least three scores; 2) combining the scores from step 1) in a multiple linear regression to obtain a new multi-targeted score; 3) optionally sorting the multi-targeted score obtained in step 2) in a classification of liver lesion stages or grades, thereby determining to which liver lesion stage or grade the subject belongs based on his/her multi-targeted score. Also disclosed is a single multi-targeted non-invasive test obtained by the combination of single-targeted non-invasive tests providing a unique score and a unique classification with improved accuracy compared to single-targeted diagnostic tests.

Abstract: A method for identifying a microorganism to be identified, which includes the following steps: obtaining an Excitation-Emission EEM of the microorganism to be identified, analysing the main components of the EEM matrix using at least one reference EEMr matrix, projecting the result of the analysis onto a plane defined by two main components, and identifying the microorganism to be identified.

Abstract: The treatment of cancer using platinum-based compounds includes certain drawbacks such as biocompatibility, loading efficacy, leakage of drugs during storage and in the bloodstream, more particularly due to the nature of the nanocarriers for platinum delivery. A nanosystem that allows improving platinum-based drug in vivo performance, kinetics and efficacy. In particular, nanoparticles useful as drug delivery system, these nanoparticles being formed from at least: (a) platinum-based drug, (b) poly-L-arginine, and (c) hyaluronic acid. Particularly, these nanoparticles have been tested in terms of entrapment efficiency and also carried out in vitro experiments in 2D cell culture (viability studies on B6KPC3, A549 and HT-29 cells) and 3D cell model (spheroids made of HTC-116) and in vivo experiments (by injecting intravenously to mice the nanoparticles or comparative oxaliplatin solution) to prove their efficiency.

Abstract: A system of tracing a dental prosthesis, the prosthesis including an electrical power source coupled with a radio-communications signals transmitter capable of assuming a weakly active state in which it periodically sends out signals at a first transmission frequency, and a highly active state in which it periodically sends out signals at a second, higher transmission frequency, and a presence sensor for sensing presence of the prosthesis in a mouth of a user, capable of delivering information on absence of the prosthesis in the mouth. The transmitter is configured to pass from the weakly active state to the highly active state when the sensor delivers information on absence of the prosthesis in the mouth. The system also includes a base forming a support of the dental prosthesis when not worn by a user, and the transmitter assumes the weakly active state on detecting the prosthesis in proximity to the base.

Abstract: A method for implementing an adapted patient care for an individual suffering from liver fibrosis after assessing liver fibrosis progression in the individual, and thus determining whether the individual is a slow, medium or fast fibroser. Also, a method for treating an individual suffering from liver fibrosis and identified as a fast fibroser, which includes the steps of identifying the individual as a fast fibroser by assessing fibrosis progression and treating the individual by administering without delay at least one therapeutic agent for treating liver fibrosis, or for treating the underlying cause responsible for liver fibrosis, or both.

Abstract: A method and system for stimulating an individual in order to favour use of a paretic member with respect to a healthy member that includes an element placed on the paretic member of the individual and an object placed in the vicinity of the individual. The object includes circuitry causing the device to evaluate the distance separating the element placed on the paretic member and the object, activate a scenario for generating at least one audible and/or visual and/or somaesthetic signal if the distance separating the element placed on the paretic member and the object is less than a given distance, storing and updating information whenever the distance between the element placed on the paretic member and the object is less than the given distance.

Abstract: Disclosed is a compound of formula (Ia) for the use thereof in the treatment or prevention of diseases relating to the instability of mitochondrial DNA.

Abstract: A method for assessing the presence and/or severity of fibrotic NASH in a subject, including measuring cytokeratin 18 (CK-18), aspartate aminotransferase (AST) and Homeostasis model assessment of insulin resistance (HOMA) in a sample of the subject. Also, a non-invasive accurate blood test for diagnosing fibrotic NASH including the determination of a score based on the combination of CK-18, AST and HOMA. Further, a method for treating fibrotic NASH and a method for monitoring treatment response.

Abstract: A method for assessing the presence and/or the severity of a lesion in an organ or tissue of a subject through automated analysis of at least one image of the organ or tissue is provided. In particular, the organ or tissue is a liver organ or liver tissue. The method includes the calculation of a score that combines descriptors of the image, and includes the steps of: a) measuring on the image at least two descriptors of the image, b) mathematically combining the descriptors in a score; and c) assessing the presence and/or the severity of a lesion in the organ or tissue based on the value of the score calculated at step b).

Abstract: A method for displaying at least two medical images, each medical image highlighting at least one feature, including steps of obtaining a 2D medical image, identifying at least two features on the obtained medical image, generating masks showing the identified features, each mask highlighting at least one of the identified features, generating a set of at least two medical images, each medical image highlighting at least one of the identified features by superimposing at least one of the masks on the obtained medical image, and displaying the set of at least two generated medical images, one after the other. The invention also relates to a microprocessor comprising a computer algorithm to perform the method of the invention and to a system comprising said microprocessor and a visualizing means.

Abstract: Method for providing a reliable non-invasive diagnostic test of the presence and/or severity of a disease, and associated software and expert system includes: a. collecting a diagnostic index, called Initial Index, preferably a score, b. calculating the Dispersion Index of the collected Initial Index, c. analyzing the reliability of each data by identifying if at least one data of index collected in step a) is an abnormal, inconsistent and/or a non-homogeneous data, or is responsible for a greater decrease in the Dispersion Index than that observed with other data, d. if a data is an abnormal, inconsistent and/or non-homogeneous data, or a data lowering a Dispersion Index, generating an Event Alert, e. if an Event Alert is generated, calculating new indexes, f. replacing the Initial Index including an abnormal, inconsistent and/or non-homogeneous data or a data affecting the Dispersion Index, with an Alternative, Estimated or a Mixed Index.

Abstract: The present invention relates to a method for assessing the presence and/or the severity of a lesion in an organ or tissue of a subject through automated analysis of at least one image of said organ or tissue, wherein said organ or tissue is preferably a liver organ or liver tissue, comprising the calculation of a score combining descriptors of said image, wherein said method comprises the steps of: a. measuring on said at least one image at least two descriptors of said at least one image; b. mathematically combining said at least two descriptors in a score; and c. assessing the presence and/or the severity of a lesion in the organ or tissue based on the value of the score calculated at step (b).

Abstract: This invention relates to method of diagnosing the presence and/or severity of a liver pathology and/or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, said data being selected from the group consisting of medical imaging data and clinical measurements, said combination being performed through a mathematical function. This invention also relates to a method wherein the combination through a mathematical function, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, is performed at least twice and the at least two resulting scores are combined in an algorithm based on the diagnostic reliable intervals.

Abstract: The present invention relates to a non-invasive method for assessing the presence and/or severity of a lesion in an organ of an animal, including a human, said method comprising carrying out at least one non-invasive test resulting in a value, preferably a score result, and positioning the at least one value or score result in a class of a detailed classification, such as, for example, a detailed classification based on population percentiles, or on a reliable diagnostic interval (RDI), to be crossed with another RDI. The present invention also relates to a device, preferably a meter, carrying out the non-invasive method of the invention.

Abstract: The invention relates to a method of diagnosing the presence and/or severity of a hepatic pathology and/or of monitoring the effectiveness of a curative treatment against a hepatic pathology in an individual, comprising the establishment of at least one non-invasive diagnostic score, in particular a diagnostic score for portal and septal fibrosis and/or an estimate score for the fibrosis area and/or an estimate score for the fractal dimension.

Abstract: The present invention relates to a non-invasive method for assessing liver fibrosis progression in an individual, said method comprising the steps of calculating the ratio of fibrosis level to cause duration and to a non-invasive method for assessing liver fibrosis progression in an individual, said method comprising the steps of measuring, at two different times t1 and t2, the fibrosis levels FL (t1) and FL (t2) and calculating the ratio FL (t2)?FL (t1) to (t2?t1) and to a non-invasive method for assessing if an individual is a slow, medium or fast fibroser.

Abstract: An in-vitro non-invasive method for quantifying the lesions of the liver of the patient with metabolic steatosis addressing a diagnostic target, i.e. fibrosis, steatosis and/or steato-hepatitis (NASH) and measuring at least one marker selected from the group consisting of biomarkers and possibly clinical markers and possibly scores, the biomarkers being selected from the group consisting of glycemia, AST (aspartate aminotransferase), ALT (alanine aminotransferase), AST/ALT, AST.

Abstract: This invention relates to method of diagnosing the presence and/or severity of a liver pathology and/or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, said data being selected from the group consisting of medical imaging data and clinical measurements, said combination being performed through a mathematical function. This invention also relates to a method wherein the combination through a mathematical function, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, is performed at least twice and the at least two resulting scores are combined in an algorithm based on the diagnostic reliable intervals.